Claims for Patent: 11,903,953

Summary for Patent: 11,903,953

Title:	Remdesivir treatment methods
Abstract:	Provided herein are methods of treating or preventing a viral infection in a subject comprising administering a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof, wherein the subject is not being treated with chloroquine, or an analog or salt thereof.
Inventor(s):	Tomas Cihlar
Assignee:	Gilead Sciences Inc
Application Number:	US18/128,850
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,903,953
Patent Claims:	1. A method of treating a viral infection in a human in need thereof, the method comprising administering to the human an antiviral compound; wherein the human has not been administered chloroquine, or an analog or salt thereof; the antiviral compound is converted to a compound of Formula II, or a pharmaceutically acceptable salt thereof, upon administration to the human; and the concentration of the compound of Formula II in plasma or blood is optimized in the absence of chloroquine, or an analog or salt thereof. 2. The method of claim 1, wherein the human has not been administered chloroquine, or an analog thereof, within 1 day prior to the treatment of the viral infection. 3. The method of claim 1, wherein the human has not been administered chloroquine, or an analog thereof, within 10 days prior to the treatment of the viral infection. 4. The method of claim 1, wherein the human has a plasma or blood concentration of the chloroquine, or an analog or salt thereof, of less than 50 ng/mL, at the time a first dose of the antiviral compound is administered to the human. 5. The method of claim 1, wherein the plasma or blood concentration of the compound of Formula II in the human is higher than a second concentration of a compound of Formula II in a reference human treated with chloroquine, or an analog or salt thereof. 6. The method of claim 1, wherein the antiviral compound is a compound of Formula I, Formula Ia, or Formula Ib, or a pharmaceutically acceptable salt thereof: 7. The method of claim 1, wherein the viral infection is caused by SARS-CoV-2. 8. The method of claim 1, wherein the antiviral compound is administered intravenously. 9. The method of claim 1, wherein the antiviral compound is administered by inhalation. 10. The method of claim 1, wherein the antiviral compound is administered orally. 11. The method of claim 1, wherein the chloroquine, or an analog or salt thereof, is chloroquine, desethylchloroquine, hydroxychloroquine, desethylhydroxychloroquine, or bisdesethylhydroxychloroquine, or a pharmaceutically acceptable salt thereof. 12. The method of claim 11, wherein the chloroquine, or an analog or salt thereof, is chloroquine, or a pharmaceutically acceptable salt thereof. 13. The method of claim 12, wherein the chloroquine, or an analog or salt thereof, is chloroquine phosphate. 14. The method of claim 11, wherein the chloroquine, or an analog or salt thereof, is hydroxychloroquine, or a pharmaceutically acceptable salt thereof. 15. The method of claim 14, wherein the chloroquine, or an analog or salt thereof, is hydroxychloroquine sulfate.